Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arthur Lui

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Journal of the Royal Statistical Society. Series C, Applied Statistics|June 16, 2023
A Bayesian feature allocation model for identifying cell subpopulations using CyTOF dataArthur Lui, Juhee Lee, Peter F Thall, et al.
JCO Precision Oncology|February 1, 2022
Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-AnalysisLarissa J Vos, Dimas Yusuf, Arthur Lui, et al.
CMAJ Open|March 2, 2019
Effect of proximity to specialty care on outcomes for biliary cancers: a population-based retrospective cohort studyYuan Xu, Sue Steckle, Arthur Lui, et al.
Current Oncology (Toronto, Ont.)|January 16, 2021
A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, CanadaCarissa Beaulieu, Arthur Lui, Dimas Yusuf, et al.
Investigational New Drugs|May 5, 2018
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomaArthur Lui, Karen Mulder, Christine Brezden-Masley, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Journal of the Royal Statistical Society. Series C, Applied Statistics|June 16, 2023
A Bayesian feature allocation model for identifying cell subpopulations using CyTOF dataArthur Lui, Juhee Lee, Peter F Thall, et al.
JCO Precision Oncology|February 1, 2022
Predictive and Prognostic Properties of Human Equilibrative Nucleoside Transporter 1 Expression in Gemcitabine-Treated Pancreatobiliary Cancer: A Meta-AnalysisLarissa J Vos, Dimas Yusuf, Arthur Lui, et al.
CMAJ Open|March 2, 2019
Effect of proximity to specialty care on outcomes for biliary cancers: a population-based retrospective cohort studyYuan Xu, Sue Steckle, Arthur Lui, et al.
Current Oncology (Toronto, Ont.)|January 16, 2021
A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, CanadaCarissa Beaulieu, Arthur Lui, Dimas Yusuf, et al.
Investigational New Drugs|May 5, 2018
A multicentre, open-label phase II study of Irinotecan, capecitabine (Xeloda®), and Oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinomaArthur Lui, Karen Mulder, Christine Brezden-Masley, et al.
Pageof 1